Company
Headquarters: Madison, WI, United States
Founded: 1995
Employees: 6,420
CEO: Mr. Kevin T. Conroy
$19.31 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $222.61 B |
| Danaher | $164.98 B |
| Siemens Healthineers AG | $57.84 B |
| IDEXX Laboratories, Inc. | $53.62 B |
| Lonza Group Ltd | $47.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $3.08 B |
| EBITDA | $30.3 M |
| Gross Profit TTM | $2.14 B |
| Profit Margin | -32.01% |
| Operating Margin | -0.12% |
| Quarterly Revenue Growth | 20.10% |
Exact Sciences Corporation has the following listings and related stock indices.
Stock: NASDAQ: EXAS wb_incandescent
Stock: FSX: EXK wb_incandescent
Cologuard
Founder(s): Stanley Lapidus, Anthony P. Shuber
Kevin Conroy (Chairman, President & CEO) Graham Lidgard (Chief Science Officer)